Climb Biotherapeutics, Inc. (CLYM)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway
Climb Bio, Inc. maintains a Buy rating, driven by budoprutug's strong phase 1b and long-term data in primary membranous nephropathy [pMN]. CLYM's phase 2 PrisMN trial in pMN, with initial data expected 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug's versatility, including a subcutaneous formulation and broad B-cell depletion, positions CLYM for competitive advantage in autoimmune disorders.
Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year?
Here is how Climb Bio, Inc. (CLYM) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Climb Biotherapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GS George Song Superstring Capital Management LP | 199,209 | $1.36M | $2.28M | $914,368.95 | 67.01% |
 Zachary Canonico DIADEMA PARTNERS LP | 286,126 | $1.96M | $3.27M | $1.31M | 67.01% |
Climb Biotherapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LG Leland Gershell Oppenheimer | 10,216.31 | $100,091.94 | $116,874.54 | $16,782.6 | 16.77% |
| DB Danielle Brill Truist Securities | 823.06 | $6,149.05 | $9,415.79 | $3,266.74 | 53.13% |
| JH Julian Harrison BTIG | 367.46 | $2,910.3 | $4,203.7 | $1,293.4 | 44.44% |
| GL Geulah Livshits Chardan Capital | 2,399.84 | $27,330.49 | $27,454.2 | $123.71 | 0.45% |
| JC Joseph Catanzaro Mizuho | 854.14 | $7,450.92 | $9,771.35 | $2,320.43 | 31.14% |
Climb Biotherapeutics, Inc. (CLYM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Climb Biotherapeutics, Inc. ever had a stock split?
Climb Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Aoife Brennan BCh MMSc CEO | NASDAQ (NMS) Exchange | 28658R106 CUSIP |
| US Country | 17 Employees | - Last Dividend | - Last Split | 10 Aug 2021 IPO Date |
Overview
Eliem Therapeutics, Inc. is a clinical-stage biotechnology organization with a focal commitment to innovating therapeutic solutions for a range of neuronal excitability disorders, which encompass a broad spectrum of conditions affecting both the peripheral and central nervous systems. These disorders, often characterized by their chronic nature and significant impact on quality of life, include chronic pain, psychiatric conditions, epilepsy, and more. As such, Eliem Therapeutics dedicates its research and development efforts to crafting drugs that not only address these conditions but also fill the void left by current medical treatments. Founded in 2018 and based in Redmond, Washington, the company stands as a burgeoning entity in the biotechnological landscape, poised to contribute significantly to the fields of chronic pain management, psychiatry, and neurology.
Products and Services
- ETX-123
ETX-123 is Eliem Therapeutics' pioneering drug candidate, representing a novel approach in the treatment of neuronal excitability disorders such as epilepsy, chronic pain, and depression, among others. This compound operates as a Kv7.2/3 potassium channel opener, a mechanism that is currently in the preclinical stage of development. Through its action, ETX-123 aims to modulate neuronal excitability, which could potentially offer a therapeutic benefit for a variety of conditions marked by abnormal neuronal firing or signaling.
- ETX-155
Another significant asset in Eliem Therapeutics' portfolio is ETX-155, a drug that has already progressed to a Phase 2a clinical trial. ETX-155 is being explored for its potential in treating major depressive disorder (MDD) and focal onset seizures, indicating its broad therapeutic application in both psychiatric and neurological domains. By advancing ETX-155 through the clinical development phases, Eliem Therapeutics demonstrates its commitment to providing innovative solutions for individuals grappling with these debilitating conditions.
